$PG

Procter & Gamble (PG) Q4 2026 Earnings Call Transcript

Procter & Gamble (PG) reported fiscal 2026 results in an earnings call transcript. Organic sales grew more than 1% for the year, and core EPS rose 1% to $6.89. Core operating margin fell 70 bps. Q4 core EPS was $1.43, down 3%. P&G raised its dividend 3% and returned over $15B to shareholders.

Original reporting
Published Aug 9, 2026, 8:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 8:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Procter & Gamble (PG) Q4 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PGNeutralMed
01

Why it matters

The transcript provides concrete earnings and operating metrics (organic sales, core EPS, gross and operating margin changes, free cash flow productivity) and qualitative drivers (trade dynamics, input-cost spikes, sell-out vs sell-in disconnect) that can drive revisions to 2027 expectations.

02

Market read

Traders can use the disclosed Q4 and FY metrics plus the sell-out vs sell-in and trade/input-cost explanations to update near-term earnings and margin expectations for PG.

03

What to watch

Margin commentary attributes part of the quarter to higher energy and transportation costs; traders may underweight how persistent those cost spikes are into fiscal 2027.

Relevance 8/10Novelty 7/10Timing: pre-market today, earnings call transcript for Q4 and FY 2026

Background

This is a transcript of Procter & Gamble’s Q4 and fiscal 2026 earnings call, covering performance by category and region, margin and cash flow productivity, and shareholder returns.

Company-level read

Ticker impact

$PGNeutralMedium confidence
Context

P&G reports fiscal 2026 results and Q4 core EPS of $1.43, with margin pressure from higher input costs and tariff refund offsets.

Expected impact

Likely modest volatility around margin and demand-read-through, with focus on whether share stabilization and cost productivity can offset trade and input-cost headwinds.

Evidence & confidence

The text includes specific Q4 and FY metrics (organic sales, core EPS, gross and operating margin changes, free cash flow productivity) plus commentary on sell-out vs sell-in and trade dynamics, which are key drivers for consumer staples earnings revisions.

Market effects

Signals ongoing margin sensitivity for consumer staples to energy, transportation, and materials, and the role of tariff refunds and productivity to cushion earnings.

Highlights Greater China organic sales growth (+4%) and U.S. share improvement in the back half, which can influence regional demand read-through for staples peers.

Emphasizes e-commerce mix (20% of sales) and inventory-driven sell-out vs sell-in gaps, relevant for broader retail and consumer demand interpretation.

Counterpoint

Despite reported share stabilization, the sell-in weakness and inventory dynamics could mean underlying demand is softer than headline organic sales suggest.

Key entities

  • Procter & Gamble

    PG discusses fiscal 2026 performance, Q4 results, margin/cost drivers, and shareholder returns, and frames plans for fiscal 2027 growth.

Related articles

$PGMedAI 8/10

P&G’s Wellness Focus Grows Following US$3.8bn Thorne Deal

Procter & Gamble (P&G) said it will expand its health care and wellness portfolio after agreeing to buy Thorne for US$3.8bn. P&G plans to broaden a portfolio that includes Vicks, Crest, Oral-B and supplements such as Align Probiotic. Thorne’s revenue rose from about US$229m (2022) to over US$500m (2025), with US$650m targeted in 2026; deal closes later in 2026 pending approvals.

$PGMed

Procter & Gamble acquires dietary supplement manufacturer

Procter & Gamble will acquire dietary supplement maker Thorne for $3.8 billion, according to the companies. P&G, owner of brands including Ariel, Gillette, Oral-B, and Pampers, said the deal targets its health and wellness business. Thorne, founded in 1984, went public in 2021 and was taken private in 2023 by L Catterton.

$PGMedAI 9/10

P&G Intensifies Wellness Push With Latest Acquisition

Procter & Gamble (P&G) will acquire supplements maker Thorne for $3.8 billion in cash from L Catterton, according to the companies. P&G said the deal supports its health and wellness strategy. Thorne had forecast $290 million sales for 2023 and CNBC reported $650 million for 2024. P&G also forecast slower annual sales growth.

$PGMed

Wellness Briefing: A new class of oral care disruptors hopes to shake up the space with novel offerings, plus news

The U.S. oral-care market is $12.36B (2026 est.) and projected to reach $14.56B by 2031, according to Mordor Intelligence. New DTC brands Evenmouth, Bastét and Köppen are launching microbiome or hydroxyapatite-based products and multi-step systems. Incumbents Colgate-Palmolive, P&G, Unilever and Kenvue face slower oral-care sales; P&G CFO said it is deciding how to innovate. Separately, P&G will buy Thorne for $3.8B.